Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lonardi

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
ESMO Open|March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysisR Cohen, M Raeisi, B Chibaudel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
ESMO Open|April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide datasetM M Germani, G Vetere, F Santamaria, et al.
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
ESMO Open|November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trialsE Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyE Van Cutsem, T Yoshino, H J Lenz, et al.
Clinical and Experimental Immunology|May 24, 2014
Rapid reconstitution of functionally active 6-sulfoLacNAc(+) dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplantE Mimiola, O Marini, O Perbellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trialF Petrelli, E Rulli, R Labianca, et al.
Pathologica|September 8, 2012
Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissueH Rizvi, J C Paterson, S Tedoldi, et al.
ESMO Open|April 17, 2024
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experienceR Moretto, M M Germani, B Borelli, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
ESMO Open|March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysisR Cohen, M Raeisi, B Chibaudel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
ESMO Open|April 13, 2024
Treatment of patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide datasetM M Germani, G Vetere, F Santamaria, et al.
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
ESMO Open|November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trialsE Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyE Van Cutsem, T Yoshino, H J Lenz, et al.
Clinical and Experimental Immunology|May 24, 2014
Rapid reconstitution of functionally active 6-sulfoLacNAc(+) dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplantE Mimiola, O Marini, O Perbellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trialF Petrelli, E Rulli, R Labianca, et al.
Pathologica|September 8, 2012
Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissueH Rizvi, J C Paterson, S Tedoldi, et al.
ESMO Open|April 17, 2024
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experienceR Moretto, M M Germani, B Borelli, et al.
Pageof 12